Crcm LP purchased a new stake in shares of Burning Rock Biotech Limited (NASDAQ:BNR - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 325,969 shares of the company's stock, valued at approximately $2,200,000. Burning Rock Biotech comprises 0.9% of Crcm LP's portfolio, making the stock its 5th largest position. Crcm LP owned about 3.18% of Burning Rock Biotech at the end of the most recent reporting period.

Shares of NASDAQ BNR opened at $4.90 on Tuesday. Burning Rock Biotech Limited has a one year low of $2.62 and a one year high of $8.99. The firm's 50 day simple moving average is $6.60 and its two-hundred day simple moving average is $5.27. The stock has a market capitalization of $50.20 million, a P/E ratio of -1.63 and a beta of 0.55.

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Burning Rock Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Burning Rock Biotech wasn't on the list.

While Burning Rock Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.